In male C57BL/6J mice fed a 45% high-fat diet for 14 weeks to induce metabolic dysfunction-associated steatotic liver disease (MASLD), a subsequent 12-cycle 5:2 intermittent fasting regimen (2 fasting days per week, ad libitum eating otherwise) significantly improved grip strength, skeletal muscle cross-sectional area, and hepatic steatosis — without reducing cumulative caloric intake. Key mechanisms included restored intestinal barrier integrity (upregulated tight-junction genes), lower circulating LPS, enrichment of beneficial gut bacteria (Limosilactobacillus reuteri, Faecalibaculum rodentium), upregulated microbial secondary bile acid biosynthesis, and reduced free fatty acid accumulation in both liver and skeletal muscle.
The gut–bile acid–muscle axis emerging here is scientifically compelling. Secondary bile acids signal through receptors such as TGR5 and FXR to suppress systemic inflammation and modulate muscle protein metabolism — a pathway largely ignored in MASLD research until recently. The finding that fasting improved muscle quality without cutting total calories strengthens the case that meal timing, not just caloric deficit, drives metabolic benefit.
Critical limitations: this is entirely mouse work. Rodent fasting physiology differs substantially from humans — two fasting days represent a proportionally larger metabolic stress in mice. Whether the gut microbiome remodeling seen here translates to humans undertaking 5:2 protocols remains unproven. Human 5:2 trials to date have focused on liver fat and weight, rarely on muscle mass. This study is incremental but mechanistically rich, flagging microbiome-bile acid signaling as a promising target for future human intervention trials in MASLD-associated sarcopenia.